HC Wainwright Reaffirms Buy Rating for Outlook Therapeutics (NASDAQ:OTLK)

Outlook Therapeutics (NASDAQ:OTLK)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a research report issued on Friday,Benzinga reports. They currently have a $30.00 price target on the stock.

Several other research firms have also weighed in on OTLK. Chardan Capital reiterated a “neutral” rating on shares of Outlook Therapeutics in a report on Monday, December 2nd. BTIG Research cut their price objective on Outlook Therapeutics from $50.00 to $9.00 and set a “buy” rating on the stock in a report on Friday, November 29th. One analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $32.73.

Outlook Therapeutics Trading Down 4.8 %

Outlook Therapeutics stock opened at $2.19 on Friday. The firm has a market capitalization of $54.55 million, a P/E ratio of -0.24 and a beta of 0.53. The business has a 50-day moving average of $2.78 and a 200-day moving average of $5.39. Outlook Therapeutics has a 1 year low of $0.87 and a 1 year high of $12.85.

Outlook Therapeutics (NASDAQ:OTLK) last issued its earnings results on Friday, December 27th. The company reported ($0.77) EPS for the quarter, beating the consensus estimate of ($0.83) by $0.06. Research analysts anticipate that Outlook Therapeutics will post -2.33 EPS for the current fiscal year.

Institutional Investors Weigh In On Outlook Therapeutics

Several institutional investors have recently bought and sold shares of OTLK. Christensen King & Associates Investment Services Inc. acquired a new position in Outlook Therapeutics during the third quarter worth $55,000. AQR Capital Management LLC acquired a new stake in shares of Outlook Therapeutics in the second quarter valued at about $75,000. Barclays PLC increased its position in shares of Outlook Therapeutics by 677.4% in the third quarter. Barclays PLC now owns 20,943 shares of the company’s stock valued at $111,000 after acquiring an additional 18,249 shares during the last quarter. XTX Topco Ltd bought a new stake in Outlook Therapeutics during the third quarter worth about $199,000. Finally, Squarepoint Ops LLC acquired a new position in Outlook Therapeutics during the second quarter valued at approximately $232,000. Institutional investors own 11.20% of the company’s stock.

About Outlook Therapeutics

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.